Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
The New England Journal of Medicine
|
April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Nature Medicine
|
May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial
Christoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
American Journal of Hematology
|
November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Andrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 18, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
The New England Journal of Medicine
|
April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Nature Medicine
|
May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial
Christoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
American Journal of Hematology
|
November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Andrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 18, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
Page
of 9